Statin use decreases the risk of disease progression after surgery for localized renal cell carcinoma (RCC), researchers reported in The Journal of Urology (2014;191:914-919).
Of 2,608 patients who underwent surgery for RCC from 1995-2010, 699 (27%) were statin users at the time of their operation. Their pathologic characteristics were similar to those of non-users.
At a median follow-up of 36 months, the researchers observed 247 progression events. Statin use was associated with a significant 33% reduction in progression risk, according to a research team led by Paul Russo, MD, of Memorial Sloan-Kettering Cancer Center in New York.